¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"specific reaction rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
¿µ¹® reaction formation ÇÑ±Û ¹Ýµ¿Çü¼º, ¹ÝÀÀÇü¼º
¼³¸í   
  ¾ï¾Ðº¸´Ù ´õ Àû±ØÀûÀΠ¹æ¾î¸ÞÄ¿´ÏÁòÀ̸ç, ¹«ÀǽÄÀûÀΠ»ý°¢, ¼Ò¿ø, Ã浿ÀÌ ³Ê¹«³ªµµ ¹Þ¾Æµé¿©Áú ¼ö ¾ø´Â °ÍÀÏ °æ¿ì¿¡ À̿ʹ Á¤¹Ý´ë ¹æÇâÀÇ °ÍÀ» °­Á¶ÇÔÀ¸·Î½á ±×·± ¹«ÀǽÄÀûÀΠ°ÍµéÀÌ ÀǽĵÇÁö ¾Ê°Ô Çϴ °úÁ¤. ¿¹¸¦ µé¸é °¡Àå °¡ÇÐÀûÀΠ¼º°ÝÀÇ »ç¶÷ÀÌ »ýÃ¼ÇØºÎ ¹Ý´ë·ÐÀÚ°¡ µÇ´Â °æ¿ì¸¦ µé ¼ö ÀÖ´Ù. À̰ÍÀº ¶Ç °¡½¿ ±íÀÌ Àá°ÜÀִ µÎ·Á¿òÀÌ ÀǽĵǴ °ÍÀ» ÇÇÇϱâ À§Çؼ­ µÎ·Á¿òÀÇ ´ë»óÀÌ µÇ´Â Çൿ¿¡ °ñ¸ôÇϴ °æ¿ìµµ Æ÷ÇÔÀÌ µÈ´Ù. ¿¹¸¦ µé¸é, ³²ÀÚ¿¡°Ô »óó¹ÞÁö ¾ÊÀ»±î Çϴ µÎ·Á¿ò¿¡ °¡µæ Âù ¼Ò³à°¡ ÀÌ °°Àº µÎ·Á¿òÀ» ºÎÁ¤ÇÏ·Á´Â ¼ö´ÜÀ¸·Î ³­ÀâÇÑ ¼ºÇàÀ§¿¡ °ñ¸ôÇϴ °æ¿ì°¡ ÀÖ´Ù. ¶Ç ÀüóÀÇ Àڳฦ ¹Ì¿öÇϴ °è¸ð°¡ ¿ÀÈ÷·Á Áö³ªÄ¥ Á¤µµ·Î ±× ¾ÆÀ̸¦ ±Í¿©¿öÇϴ ÀÏ µûÀ§ÀÌ´Ù. 
¿µ¹® complement fixation reaction ÇÑ±Û º¸Ã¼°áÇÕ ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ
¼³¸í   
  Ç×ü¿ÍÀÇ ¹ÝÀÀ¿¡ À־ º¸Ã¼¿Í °áÇÕÇϴ Ç×ü¸¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î, ÀÌ ¹ÝÀÀÀº ÃÖÃÊ¿¡ ±âÁöÇ׿ø, ÇǰËÇ÷û ¹× º¸Ã¼¸¦ È¥ÇÕÇÑ´Ù. Á¦2´Ü°è¿¡¼­´Â ÀûÇ÷±¸¿Í À̰Ϳ¡ ´ëÀÀÇϴ ¿ëÇ÷¼ÒÀǠȥÇÕ¾×À» °¡ÇÑ´Ù. º» ¹ÝÀÀÈÄ ¿ëÇ÷ÀÌ ÀϾÁö ¾ÊÀ¸¸é º»Ã¼´Â Ç׿øÇ×ü°áÇÕ¹°¿¡ °áÇÕÇÑ °ÍÀÌ µÇ¾î ¾ç¼ºÀÌ µÇÁö¸¸, ¿ëÇ÷ÀÌ ÀϾ °æ¿ì º¸Ã¼´Â °áÇÕÇÏÁö ¾Ê¾Æ ¼ÒºñµÇÁö ¾Ê±â ¶§¹®¿¡ À½¼ºÀÌ µÈ´Ù. º» ¹ÝÀÀÀº ±âÁöÇ÷ûÀ» ½á¼­ Ç׿ø°ËÃâ¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ¸¶ÀÌÄÚÇö󽺸¶, ¸®ÄÉí, Å¬¶ó¹Ìµð¾Æ, ¹ÙÀÌ·¯½º, ¸Åµ¶ µîÀÇ Áø´Ü¿¡ ¾²ÀδÙ.
  
  
¿µ¹® transfusion reaction ÇÑ±Û ¼öÇ÷ºÎÀÛ¿ë, ¼öÇ÷¹ÝÀÀ
¼³¸í   
  ¼öÇ÷ÇÏ¿´À» ¶§¿¡ È¯ÀÚ¿¡°Ô ÀϾ´Â ¹ÝÀÀ. ¾Ë·¹¸£±â ¹ÝÀÀ°ú ¿ëÇ÷ ¹ÝÀÀÀÌ ÀÖ´Ù.
¿µ¹® graft versus host reaction ÇÑ±Û ÀÌ½ÄÆí´ë ¼÷ÁÖ¹ÝÀÀ
¼³¸í   
  ¸é¿ªÀ̶õ ÀÚ½ÅÀÇ °Í°ú ÀÚ½ÅÀÇ °ÍÀÌ ¾Æ´Ñ °ÍÀ» ±¸ºÐÇØ¼­ ÀÚ½ÅÀÇ °ÍÀÌ ¾Æ´Ñ °ÍÀ» °ø°ÝÇÏ¿© »ý¹°ÇÐÀû È°¼ºÀ» ¾ø¾Ö°Å³ª Á¦°ÅÇϴ °ÍÀÌ´Ù. ÀÌ ¸é¿ªÀº ÁַΠÇ÷¾×¿¡ Àִ ¼¼Æ÷¿¡ ÀÇÇØ¼­ ÀÌ·ç¾îÁø´Ù. Æ¯È÷ ¸²ÇÁ±¸´Â ÀÌ ¸é¿ª¿¡ ÁßÃßÀûÀΠ¿ªÇÒÀ» Çϴ ¼¼Æ÷ÀÌ´Ù. ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀÀ̶ó´Â °ÍÀº À̽ĵǾî¿Â Á¶Á÷¿¡ Á¸ÀçÇϴ ŸÀÎÀÇ Ç÷±¸µéÀÌ ¼÷ÁÖÀÇ ¼¼Æ÷¸¦ °ø°ÝÇϴ °ÍÀ» ¸»ÇÑ´Ù. Áï À̽ĵǾî¿Â Á¶Á÷°ú ÇÔ²² µé¾î¿Â Ç÷±¸µéÀÌ À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ ¼¼Æ÷¸¦ Å¸ÀÎÀÇ °ÍÀ¸·Î ÀÎÁöÇØ¼­ °ø°ÝÇϴ Çö»óÀÌ´Ù. À̰ÍÀº À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ ¸é¿ª»óŰ¡ Á¤»óÀûÀÏ °æ¿ì¿¡´Â ÀϾÁö ¾Ê´Âµ¥ ¿Ö³ÄÇϸ頸鿪»óŰ¡ Á¤»óÀÏ °æ¿ì¿¡´Â À̽ĵǾî¿Â Àå±â¿Í ´õºÒ¾î µé¾î¿Â Å¸ÀÎÀÇ Ç÷±¸µéÀ» À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ Ç÷±¸°¡ Å¸ÀÎÀÇ °ÍÀ¸·Î ÀÎÁöÇØ¼­ °ø°ÝÀ» ÇÏ°í ¼ýÀûÀ¸·Î À¯¸®ÇÏ¿© ¸ðµÎ Á×ÀÏ ¼ö°¡ Àֱ⠶§¹®ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • group-specific
    ±ºÆ¯ÀÌ-
  • group-specific antigen
    ¹«¸®Æ¯ÀÌÇ׿ø, ±ºÆ¯ÀÌÇ׿ø
  • neuron-specific enolase
    ´º·±Æ¯ÀÌ¿¡³î¶ó¾ÆÁ¦
  • organ specific antigen
    Àå±âƯÀÌÇ׿ø
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • prostate specific antigen
    Àü¸³»ùƯÀÌÇ׿ø
  • species-specific
    Á¾Æ¯ÀÌ-
  • species-specific antigen
    Á¾Æ¯ÀÌÇ׿ø
  • species-specific reactivity
    Á¾Æ¯À̹ÝÀÀ¼º
  • specific
    1. ƯÀÌ-, ƯÁ¤- 2. Á¾-
  • specific action
    ƯÀÌÀÛ¿ë
  • specific activity
    1. ºñ¹æ»ç´É 2. ºñ(Ýï)Ȱ¼ºµµ, °íÀ¯È°¼ºµµ
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
  • specific antigen
    ƯÀÌÇ׿ø
  • specific charge
    ºñÀüÇÏ, °ßÁÜÀüÇÏ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chain reaction
    ¿¬¼â¹ÝÀÀ
  • complement fixation reaction
    µµ¿òü°áÇÕ¹ÝÀÀ, º¸Ã¼°áÇÕ¹ÝÀÀ
  • cross reaction
    ±³Â÷¹ÝÀÀ
  • delayed reaction
    Áö¿¬¹ÝÀÀ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
  • inhibition reaction
    ¾ïÁ¦¹ÝÀÀ
  • initial reaction
    Ãʱâ¹ÝÀÀ
  • late reaction
    (¢¡delayed reaction) Áö¿¬¹ÝÀÀ
  • periosteal reaction
    »À¸·¹ÝÀÀ, °ñ¸·¹ÝÀÀ
  • phobic reaction
    °øÆ÷¹ÝÀÀ
  • polymerase chain reaction
    ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ, ÁßÇÕ¿¬¼â¹ÝÀÀ
  • pyrogenic reaction
    ¹ß¿­¹ÝÀÀ
  • rejection reaction
    °ÅºÎ¹ÝÀÀ
  • reversible reaction
    °¡¿ª¹ÝÀÀ
  • second order reaction
    ÀÌÂ÷¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • organ specific antigen
    Àå±âƯÀÌÇ׿ø
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • specific action
    ƯÀÌÀÛ¿ë
  • specific activity
    ºñ¹æ»ç´É, ƯÀÌȰ¼ºµµ
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
  • specific antigen
    ƯÀÌÇ׿ø
  • specific pathogen free animal
    ƯÁ¤¹«º´¿øÃ¼µ¿¹°
  • type specific antigen
    ÇüƯÀÌÇ׿ø
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú
  • specific charge
    °ßÁÜÀüÇÏ, ºñÀüÇÏ
  • specific compliance
    ƯÀÌź¼º, ƯÀÌÀ¯¼øµµ, ƯÀÌÀÀ¶ô
  • specific conductivity
    ºñÀüµµÀ²
  • specific electric conductivity
    ºñÀü±âÀüµµÀ²
  • donor-specific phage
    Á¦°øÃ¼Æ¯ÀÌÆÄÁö, ÁÖ°ÔÆ¯ÀÌÆÄÁö
  • specific disease
    ƯÀÌÁúȯ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • platelet-specific antigens
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • pneumococcal [specific] polysaccharide
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • polysaccharide, pneumococcal [specific]
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • prostate specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø
  • prostate-specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø(îñí¡àÍ÷åì¶ù÷ê«)
  • prostatic specific antigen
    Àü¸³¼± ƯÀÌÇ׿ø
  • BMR=£¾basal metabolic rate
    ±âÃÊ´ë»çÀ²
  • GFR => glomerular filtration rate
    »ç±¸Ã¼¿©°úÀ²
  • GFR= glomerular filtration rate
    »ç±¸Ã¼(ÞêϹô÷)°Å¸§·ü(×È).
  • GFR= glomerular filtration rate
    »ç±¸Ã¼°Å¸§·ü.
  • Heart rate
    ½É¹Ú¼ö(ãýÚÑâ¦)
  • MVR=£¾maximus voiding rate
    ÃÖ´ë¹è´¢À².
  • Westergren sedimentation rate
    ¿þ½ºÅͱ׷»Ä§°­¼Óµµ
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • actual death rate
    ½ÇÁ¦»ç¸Á·ü(ËàÌ¡Ë×ËÎËô).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • untoward effect =adverse reaction, unwanted reaction
    À¯ÇعÝÀÀ(êóúªÚãëë), ºÎÀÛ¿ë
  • untoward effect =adverse reaction, unwanted reaction
    À¯ÇعÝÀÀ(êóúªÚãëë), ¾àÇØ(å·úª)¹ÝÀÀ.[¾à¸®]ºÎÀÛ¿ë, ºÒ¿øÀÛ¿ë.
  • upgrading reaction => reversal reaction
    ¿ªÇà¹ÝÀÀ
  • antigen, species-specific
    Á¾Æ¯ÀÌÇ׿ø
  • antigen, tumor-specific
    Á¾¾çƯÀÌÇ׿ø
  • antigen, tumor-specific transplantation
    Á¾¾çƯÀÌ À̽ÄÇ׿ø
  • antigen,tumor-specific transplantation
    Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú.
  • bulk specific gravity
    ¿ëÀûºñÁß(é»îÝÝïñì)
  • donor-specific phage
    °ø¿©±ÕƯÀÌÆÄÁö
  • granulocyte-specific antigens
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group specific C carbohydrate
    ±ºÆ¯ÀÌ C´Ù´çü.
  • group-specific
    ±ºÆ¯ÀÌÀÇ
  • group-specific C carbohydrate
    ±ºÆ¯ÀÌ C ź¼öÈ­¹°
  • group-specific antigen
    ±º-ƯÀÌÇ׿ø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • apparent specific volume
    ¿Ü°ß(èâ̸) ºñ(Ýï)¿ëÀû(é»îÝ)
  • enzyme-specific electrode
    È¿¼ÒƯÀÌ Àü±Ø (ý£áÈ÷åì¶ï³Ð¿)
  • organ specific enzyme
    ±â°üƯÀÌÈ¿¼Ò(Ðïί÷åì¶ý£áÈ)
  • partial specific quantity
    Æíºñ·®(ø¶ÝïÕá)
  • partial specific volume
    Æíºñ¿ëÀû(ø¶Ýïé»îÝ)
  • plasma-specific enzyme
    Ç÷À寝ÀÌ È¿¼Ò(úìíì÷åì¶ý£áÈ)
  • relative specific activity
    »ó´ë ƯÀÌ È°¼ºµµ(ßÓÓß÷åì¶üÀàõÓø)
  • site-specific endonuclease
    ÀÚ¸® ƯÀ̼º(÷åì¶àõ) ¿£µµ´©Å¬¸®¿¡À̽º
  • site-specific inversion
    ÀÚ¸®Æ¯ÀÌ(÷åì¶) ¿ªÀ§(æ½êÈ)
  • site-specific recombinstion
    ÀÚ¸®Æ¯ÀÌ(÷åì¶) ÀçÁ¶ÇÕ(î¢ðÚùê)
  • specific acid-base catalysis
    ƯÀÌ »ê.¿°±â Ã˸Å(÷åì¶ß«ç¤ÐñõºØÚ)
  • specific activity
    ºñȰ¼º(ÝïüÀàõ)
  • specific adsorption
    ¼±ÅÃÈíÂø(àÔ÷Éýåó·)
  • specific dynamic action
    ƯÀÌ µ¿Àû ÀÛ¿ë(÷åì¶ÔÑîÜíÂéÄ)
  • specific extinction coefficient
    ºñÈí±¤ °è¼ö(ÝïýåÎÃÌõâ¦)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • erythrocyte sedimentation rate
    ÀûÇ÷±¸Ä§°­¼Óµµ, Ç÷ħ¼Óµµ
  • frame rate
    È­¸éÀ²
  • metabolic rate
    ´ë»çÀ²
  • molecular tumbling rate
    ºÐÀÚÅÒºí¸µÀ²
  • pulse rate
    ¸Æ¹Ú¼ö, ÆÞ½ºÀ²
  • pulse repetition rate
    ÆÞ½º¹Ýº¹À²
  • rate
    ¼Óµµ, ¾ç, À², ºñ
  • relaxation rate
    ÀÌ¿ÏÀ²
  • respiration rate
    È£Èí·ü
  • turnover rate
    ±³Ã¼À², ±³Ã¼¼Óµµ, ±³´ëÀ²
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
CPR cardiopulmonary reserve; cardiopulmonary resuscitation; centripetal rub; cerebral cortex perfusion r...
CSR central supply room; chart-stimulated recall [test]; Cheyne-Stokes respiration; continued stay revie...
PR by way of the rectum [Lat. per rectum]; far point [of accommodation] [Lat. punctum remotum]; palindr...
LR labeled release; laboratory references; laboratory report; labor room; lactated Ringer [solution]; l...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PCR-SSOP polymerace chain reaction-sequence-specific oligonucleotide probe
PCR-SSP polymerase chain reaction using sequence specific primers
SAR Specific Absorption Rate
SAR specific energy absorption rate
AR Acrosome reaction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • specific gravity test
    ºñÁß ½ÃÇè
  • specific humoral immunity
    ƯÀ̼º ü¾× ¸é¿ª
  • specific inflammation
    ƯÀ̼º ¿°Áõ
  • specific membrane receptor
    ƯÁ¤ ¸· ¼ö¿ë±â
  • specific opiate receptor site
    Ưº°ÇÑ ¾ÆÆí ¼ö¿ëºÎ
  • specific receptor
    ƯÀÌ ¼ö¿ëü, ƯÀÌ ¼ö¿ë±â
  • specific region
    ƯÀÌ ºÎÀ§
  • specific tender point site
    ƯÁ¤ ¾ÐÅëÁ¡
  • specific weight
    ºñÁß
  • tumor specific transplantation
    Á¾¾ç ƯÀ̼º À̽Ä
  • virus-specific surface antigen
    ¹ÙÀÌ·¯½º ƯÀ̼º Ç¥¸é Ç׿ø ¹ÙÀÌ·¯½º
  • absorptace rate
    Èí¼öÀ²
    ÀÎü¿¡ Á¶»çµÇ´Â ¹æ»ç¼±¿¡ ´ëÇØ ÀÎü¿¡ Èí¼öµÇ´Â ¹æ»ç¼± ¿¡³ÊÁöÀÇ ºñÀ².
  • absorption rate
    Èí¼öÀ²
    ÀÏÁ¤ ½Ã°£¿¡ »¡¾ÆµéÀÌ´Â ¼Óµµ¸¦ ³ªÅ¸³»´Â À².
  • adjusted death rate
    Á¶Á¤ »ç¸Á·ü
  • attack rate
    ¹ßº´·ü, ÀÌȯÀ²
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
myelencephalon-specific serine protease <enzyme> Specifically expressed in the nervous system; plays a role in normal homeostasis and response of spinal cord to injury.
Registry number: EC 3.4.21.-
Synonym: myelencephalon-specific protease, msp enzyme
(26 Jun 1999)
pregnancy-specific beta 1-glycoprotein A glycoprotein with the electrophoretic mobility of a beta-1 globulin. It is produced by the placental trophoblast and secreted into the maternal bloodstream during pregnancy. It can be detected 18 days after ovulation and its concentration in plasma rises steadily until, at the end of gestation, it reaches 200 mg/ml. It has been proposed as a measure of placental function for fertility control and is a candidate for an early pregnancy test.
(12 Dec 1998)
prenylated peptide-specific endoprotease <enzyme> Cleaves c-terminal tripeptide from prenylated protein having c-terminal sequence caax; race is rac and a-factor converting enzyme with same activity
Registry number: EC 3.4.14.-
Synonym: prenylated protein endoprotease, race enzyme, isoprenylated protein endopeptidase, isoprenylated protein endoprotease
(26 Jun 1999)
cytosol non-specific dipeptidase <enzyme> Also referred to as peptidase a (see synonym to penicillopepsin, EC 3.4.23.20)
Registry number: EC 3.4.13.-
Synonym: glycyl-l-leucine hydrolase, glycylleucine dipeptidase, gly-leu dipeptide peptidase, dipeptide hydrolase, glycyl-leucine dipeptidase
(26 Jun 1999)
cytotoxic T lymphocyte-specific serine protease <enzyme> Structural sequence given in first source
Registry number: EC 3.4.21.-
Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II
(26 Jun 1999)
proline-specific dipeptidylcarboxypeptidase <enzyme> From streptomyces species; removes diproline form c-terminus of proline-containing peptides such as boc-pro-pro-pro-pro or leu-pro-pro-pro-pro-pro
Registry number: EC 3.4.15.-
Synonym: pro-dpp-carboxypeptidase
(26 Jun 1999)
prostate-specific antigen <tumour marker> A simple blood test used to detect prostate cancer in men. The test measures a specific antigen normally secreted by the prostate. If cancer is developing, the prostate secretes greater amounts of prostate-specific antigen. This test is recommended for men with an enlarged prostate and an increased risk of prostate cancer.
It is an enzyme that is produced by epithelial cells of both benign and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
It is a single chain 31 kilodalton glycoprotein with 240 amino acid residues and 4 carbohydrate side chains that is a kallikrein protease.
It is found in normal seminal fluid and produced by the prostatic epithelial cells.
Elevated levels in blood serum are associated with prostatic enlargement and prostatic adenocarcinoma, and this allows early detection of cancer in many cases. In about 70% of cases, the rise is due to a cancerous condition.
No large scale clinical studies have been completed to assess the impact of testing on survival from prostate cancer, and the medical and economic value of testing remain uncertain.
Acronym: PSA
Registry number: EC 3.4.21.77
(22 Sep 2002)
pyrimidine-guanine sequence-specific ribonuclease <enzyme> From yolk granules of adult rana catesbeiana oocytes
Registry number: EC 3.1.27.-
Synonym: rc-rnase, rana catesbeiana rnase
(26 Jun 1999)
site-specific mutagenesis <cell culture, molecular biology> An in vitro technique in which an alteration is made at a specific site in a DNA molecule, which is then reintroduced into a cell. Various techniques are used, for the cell biologist, a very powerful approach to determining which parts of a protein or nucleotide sequence are critical to function.
(18 Nov 1997)
site specific mutation An alteration of the structure of a gene at a specific sequence, usually referring to experimentally produced changes in gene sequence.
(05 Mar 2000)
site-specific recombination <molecular biology> A type of recombination that occurs between two specific short DNA sequences present in the same or in different molecules. An example is the integration and excision of _ prophage.
(18 Nov 1997)
soluble specific substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
species-specific Applying only to a particular species, said of effects that vary depending on the species in question.
(09 Oct 1997)
species-specific antigen Antigenic components in the tissues and fluids of members of a species of animal, by means of which various species may be immunologically distinguished; e.g., serum albumin of horses is immunologically different from that of man, dogs, sheep, and so on.
(05 Mar 2000)
specific 1. Pertaining to a species.
2. Produces by a single kind of microorganism.
3. A remedy specially indicated for any particular disease.
4. <immunology> Pertaining to the special affinity of antigen for the corresponding antibody.
Origin: L. Specificus
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • fusion reaction
    ÇÙÀ¶ÇÕ ¹ÝÀÀ
  • nuclear reaction
    ÇÙ¹ÝÀÀ
  • protective reaction
    ¹æ¾î ¹ÝÀÀ(ÀÚÀ§,º¸º¹À» ¸ñÀûÀ¸·Î ÇÑ Æø°Ý)
  • reaction
    ¹ÝÀÛ¿ë;¹ÝÇ×;¹Ý¹ß;(Á¤Ä¡»óÀÇ)¹Ýµ¿;¿ªÇà;(ÀÚ±Ø.»ç°Ç.¿µÇ⠵ ´ëÇÑ)¹ÝÀÀ;ŵµ;Àǰß;Àλó;(°ú·Î.±äÀå.ÈïºÐ ÈÄÀÇ)Ȱ·Â°¨Åð;¹«±â·Â;¹ÝÀÀ;¹ÝÀÛ¿ë;¹Ýµ¿·Â;ÇÙ¹ÝÀÀ;¹ÝÃæ ÀÛ¿ë;Àç»ý
  • reaction engine
    (·ÎÄÏÀÇ)¿ªÃßÁø ¿£Áø
  • reaction formation
    ¹Ýµ¿ Çü¼º(»çȸÀû.µµ´öÀûÀ¸·Î ÁÁÁö ¾ÊÀº ¿å±¸³ª ¿ø¸ÁÀ» ¾ïÁ¦Çϱâ À§ÇÏ¿© ÀÌ ¿å±¸¿Í´Â ¹Ý´ë ¹æÇâÀÇ µ¶´ÜÀû ÇൿÀ» ÃëÇÏ´Â ¹«ÀǽÄÀû ÇàÀ§)
  • reaction shot
    ¾ó±¼¿¡ ³ªÅ¸³ª´Â ¹ÝÀÀÀ» Àâ´Â ¼ô;Ç¥Á¤ÀÇ Å¬·ÎÁî¾÷
  • reaction time
    ¹ÝÀÀ ½Ã°£
  • thermonuclear reaction
    ¿­ÇÙ ¹ÝÀÀ
  • at any rate
    ÇÏ¿©Æ°
  • heart rate
    ¸Æ¹Ú
  • monthly rate
    1°³¿ù ¿ä±Ý
  • rate
    ºñÀ²,À²,(º¹¼ö)¿ä±Ý,Æò°¡ÇÏ´Ù
  • ad rate
    ±¤°í·á
  • bank rate
    ¾îÀ½ÇÒÀÎÀ²;ÀºÇàÀϺ¯
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á